Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy

Jong Hyun Jhee; Hye Young Kang; Meiyan Wu; Bo Young Nam; Tae Ik Chang; Su Young Jung; Seohyun Park; Hyoungnae Kim; Hae Ryong Yun; Youn Kyung Kee; Chang Yun Yoon; Jung Tak Park; Tae Hyun Yoo; Shin Wook Kang; Seung Hyeok Han

doi:10.1515/cclm-2017-0090

Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy

Jong Hyun Jhee, Hye Young Kang, Meiyan Wu, Bo Young Nam, Tae Ik Chang, Su Young Jung, Seohyun Park, Hyoungnae Kim, Hae Ryong Yun, Youn Kyung Kee, Chang Yun Yoon, Jung Tak Park, Tae Hyun Yoo, Shin Wook Kang, Seung Hyeok Han

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Soluble CD89 (sCD89)-IgA complex plays a key role in the pathogenesis of IgA nephropathy (IgAN). However, there is a lack of evidence supporting this complex as a good biomarker for disease progression. This study aimed to evaluate the usefulness of sCD89-IgA complex for risk stratification of IgAN. A total of 326 patients with biopsy-proven IgAN were included. sCD89-IgA complex was measured by sandwich-enzyme-linked immunosorbent assay. The study endpoints were a 30% decline in estimated glomerular filtration rate (eGFR). sCD89-IgA complex levels were inversely and weakly associated with eGFR at the time of biopsy (r=-0.12, p=0.03). However, the significance between the two factors was lost in the multivariate linear regression after adjustment of clinical factors (β=0.35, p=0.75). In a multivariate Cox model, the highest (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.35-1.61; p=0.45) and middle (HR, 0.93; 95% CI, 0.46-1.89; p=0.84) tertiles of sCD89-IgA complex levels were not associated with an increased risk of developing a 30% decrease in eGFR. Furthermore, the decline rates in eGFR did not differ between groups and C-statistics revealed that the sCD89-IgA complex were not superior to clinical factors in predicting disease progression. This study found no association between sCD89-IgA complex levels and disease progression in IgAN. Although sCD89 can contribute to the formation of immune complexes, our findings suggest that the sCD89-IgA level is not a good predictor of adverse outcomes and has limited clinical utility as a biomarker for risk stratification in IgAN.

Original language	English
Pages (from-to)	75-85
Number of pages	11
Journal	Clinical Chemistry and Laboratory Medicine
Volume	56
Issue number	1
DOIs	https://doi.org/10.1515/cclm-2017-0090
Publication status	Published - 2017 Nov 27

Bibliographical note

Funding Information:
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. Financial support: This study was supported by a faculty research grant of Yonsei University College of Medicine for 2015; Dr. Wu M is supported by China Scholarship Council. Employment or leadership: None declared. Honorarium: None declared. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Publisher Copyright:
© 2018 2018 Walter de Gruyter GmbH, Berlin/Boston.

All Science Journal Classification (ASJC) codes

Clinical Biochemistry
Biochemistry, medical

Access to Document

10.1515/cclm-2017-0090

Cite this

Jhee, J. H., Kang, H. Y., Wu, M., Nam, B. Y., Chang, T. I., Jung, S. Y., Park, S., Kim, H., Yun, H. R., Kee, Y. K., Yoon, C. Y., Park, J. T., Yoo, T. H., Kang, S. W., & Han, S. H. (2017). Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy. Clinical Chemistry and Laboratory Medicine, 56(1), 75-85. https://doi.org/10.1515/cclm-2017-0090

@article{ccf82c19b2c84d648ce590714f9ec880,

title = "Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy",

abstract = "Soluble CD89 (sCD89)-IgA complex plays a key role in the pathogenesis of IgA nephropathy (IgAN). However, there is a lack of evidence supporting this complex as a good biomarker for disease progression. This study aimed to evaluate the usefulness of sCD89-IgA complex for risk stratification of IgAN. A total of 326 patients with biopsy-proven IgAN were included. sCD89-IgA complex was measured by sandwich-enzyme-linked immunosorbent assay. The study endpoints were a 30% decline in estimated glomerular filtration rate (eGFR). sCD89-IgA complex levels were inversely and weakly associated with eGFR at the time of biopsy (r=-0.12, p=0.03). However, the significance between the two factors was lost in the multivariate linear regression after adjustment of clinical factors (β=0.35, p=0.75). In a multivariate Cox model, the highest (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.35-1.61; p=0.45) and middle (HR, 0.93; 95% CI, 0.46-1.89; p=0.84) tertiles of sCD89-IgA complex levels were not associated with an increased risk of developing a 30% decrease in eGFR. Furthermore, the decline rates in eGFR did not differ between groups and C-statistics revealed that the sCD89-IgA complex were not superior to clinical factors in predicting disease progression. This study found no association between sCD89-IgA complex levels and disease progression in IgAN. Although sCD89 can contribute to the formation of immune complexes, our findings suggest that the sCD89-IgA level is not a good predictor of adverse outcomes and has limited clinical utility as a biomarker for risk stratification in IgAN.",

author = "Jhee, {Jong Hyun} and Kang, {Hye Young} and Meiyan Wu and Nam, {Bo Young} and Chang, {Tae Ik} and Jung, {Su Young} and Seohyun Park and Hyoungnae Kim and Yun, {Hae Ryong} and Kee, {Youn Kyung} and Yoon, {Chang Yun} and Park, {Jung Tak} and Yoo, {Tae Hyun} and Kang, {Shin Wook} and Han, {Seung Hyeok}",

note = "Funding Information: Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. Financial support: This study was supported by a faculty research grant of Yonsei University College of Medicine for 2015; Dr. Wu M is supported by China Scholarship Council. Employment or leadership: None declared. Honorarium: None declared. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication. Publisher Copyright: {\textcopyright} 2018 2018 Walter de Gruyter GmbH, Berlin/Boston.",

year = "2017",

month = nov,

day = "27",

doi = "10.1515/cclm-2017-0090",

language = "English",

volume = "56",

pages = "75--85",

journal = "Zeitschrift fur klinische Chemie und klinische Biochemie",

issn = "1434-6621",

publisher = "Walter de Gruyter GmbH & Co. KG",

number = "1",

}

Jhee, JH, Kang, HY, Wu, M, Nam, BY, Chang, TI, Jung, SY, Park, S, Kim, H, Yun, HR, Kee, YK, Yoon, CY, Park, JT, Yoo, TH , Kang, SW & Han, SH 2017, 'Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy', Clinical Chemistry and Laboratory Medicine, vol. 56, no. 1, pp. 75-85. https://doi.org/10.1515/cclm-2017-0090

TY - JOUR

T1 - Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy

AU - Jhee, Jong Hyun

AU - Kang, Hye Young

AU - Wu, Meiyan

AU - Nam, Bo Young

AU - Chang, Tae Ik

AU - Jung, Su Young

AU - Park, Seohyun

AU - Kim, Hyoungnae

AU - Yun, Hae Ryong

AU - Kee, Youn Kyung

AU - Yoon, Chang Yun

AU - Park, Jung Tak

AU - Yoo, Tae Hyun

AU - Kang, Shin Wook

AU - Han, Seung Hyeok

N1 - Funding Information: Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. Financial support: This study was supported by a faculty research grant of Yonsei University College of Medicine for 2015; Dr. Wu M is supported by China Scholarship Council. Employment or leadership: None declared. Honorarium: None declared. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication. Publisher Copyright: © 2018 2018 Walter de Gruyter GmbH, Berlin/Boston.

PY - 2017/11/27

Y1 - 2017/11/27

N2 - Soluble CD89 (sCD89)-IgA complex plays a key role in the pathogenesis of IgA nephropathy (IgAN). However, there is a lack of evidence supporting this complex as a good biomarker for disease progression. This study aimed to evaluate the usefulness of sCD89-IgA complex for risk stratification of IgAN. A total of 326 patients with biopsy-proven IgAN were included. sCD89-IgA complex was measured by sandwich-enzyme-linked immunosorbent assay. The study endpoints were a 30% decline in estimated glomerular filtration rate (eGFR). sCD89-IgA complex levels were inversely and weakly associated with eGFR at the time of biopsy (r=-0.12, p=0.03). However, the significance between the two factors was lost in the multivariate linear regression after adjustment of clinical factors (β=0.35, p=0.75). In a multivariate Cox model, the highest (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.35-1.61; p=0.45) and middle (HR, 0.93; 95% CI, 0.46-1.89; p=0.84) tertiles of sCD89-IgA complex levels were not associated with an increased risk of developing a 30% decrease in eGFR. Furthermore, the decline rates in eGFR did not differ between groups and C-statistics revealed that the sCD89-IgA complex were not superior to clinical factors in predicting disease progression. This study found no association between sCD89-IgA complex levels and disease progression in IgAN. Although sCD89 can contribute to the formation of immune complexes, our findings suggest that the sCD89-IgA level is not a good predictor of adverse outcomes and has limited clinical utility as a biomarker for risk stratification in IgAN.

AB - Soluble CD89 (sCD89)-IgA complex plays a key role in the pathogenesis of IgA nephropathy (IgAN). However, there is a lack of evidence supporting this complex as a good biomarker for disease progression. This study aimed to evaluate the usefulness of sCD89-IgA complex for risk stratification of IgAN. A total of 326 patients with biopsy-proven IgAN were included. sCD89-IgA complex was measured by sandwich-enzyme-linked immunosorbent assay. The study endpoints were a 30% decline in estimated glomerular filtration rate (eGFR). sCD89-IgA complex levels were inversely and weakly associated with eGFR at the time of biopsy (r=-0.12, p=0.03). However, the significance between the two factors was lost in the multivariate linear regression after adjustment of clinical factors (β=0.35, p=0.75). In a multivariate Cox model, the highest (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.35-1.61; p=0.45) and middle (HR, 0.93; 95% CI, 0.46-1.89; p=0.84) tertiles of sCD89-IgA complex levels were not associated with an increased risk of developing a 30% decrease in eGFR. Furthermore, the decline rates in eGFR did not differ between groups and C-statistics revealed that the sCD89-IgA complex were not superior to clinical factors in predicting disease progression. This study found no association between sCD89-IgA complex levels and disease progression in IgAN. Although sCD89 can contribute to the formation of immune complexes, our findings suggest that the sCD89-IgA level is not a good predictor of adverse outcomes and has limited clinical utility as a biomarker for risk stratification in IgAN.

UR - http://www.scopus.com/inward/record.url?scp=85037156566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037156566&partnerID=8YFLogxK

U2 - 10.1515/cclm-2017-0090

DO - 10.1515/cclm-2017-0090

M3 - Article

C2 - 28672768

AN - SCOPUS:85037156566

SN - 1434-6621

VL - 56

SP - 75

EP - 85

JO - Zeitschrift fur klinische Chemie und klinische Biochemie

JF - Zeitschrift fur klinische Chemie und klinische Biochemie

IS - 1

ER -

Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this